- Do Not Prescribe (DNP)
- Decision Date:
- September 2022
DNP: NICE TA812 Pralsetinib for treating RET fusion-positive
advanced non-small-cell lung cancer. NHSE commissioned.
Do Not Prescribe (DNP) Drug Classifications
- 2: Have a lack of data on safety compared with standard therapy
- 4: Have a lack of data on cost-effectiveness compared with standard therapy